Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Thermo Fisher Scientific

Evaluate

July 05, 2023

Medtech dealmaking grinds almost to a halt

M&A moves are down, venture rounds few and IPOs nonexistent.

January 11, 2023

Few big bangs in a quiet year for medtech mergers

J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.

Article image
Vantage logo
October 31, 2022

Thermo Fisher flashes the Covid cash

The $2.6bn acquisition of The Binding Site is 2022’s biggest medtech deal, but investors are unmoved.

Article image
Vantage logo
February 14, 2022

Covid test revenues to crash in 2022

Article image
Vantage logo
December 08, 2021

Covid-19 tests versus Omicron

The new variant might be able to dodge one of the PCR tests authorised in the US, the FDA says.

Article image
Vantage logo
November 29, 2021

Diagnostics groups square up to Omicron

Article image
Vantage logo
September 08, 2021

The new reality of Covid-19 testing

An evolving virus demands innovative diagnostic technologies.

Article image
Vantage logo
August 17, 2021

Covid-19 tests from Thermo Fisher and Healthineers evolve

Article image
Vantage logo
April 12, 2021

Diasorin heads to the US with $1.8bn Luminex deal

And consolidation in the diagnostics space is only just beginning.

Article image
Vantage logo
February 24, 2021

Medtech’s haves and have-nots

Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.

Article image
Vantage logo
January 19, 2021

Thermo Fisher goes shopping

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up